Recombinant GM-CSF (subcutaneous or inhaled) and B cell depleting agents such as rituximab have been used to treat autoimmune PAP due to anti-GM-CSF autoantibodies (66–68). This evidence concerns the gene CSF2 and autoimmune pulmonary alveolar proteinosis.